Back to Agenda
Session 7: Resolving HTA/Payer Uncertainties with Real World Evidence
Session Chair(s)
Karen Facey, PhD
Visiting Senior Research Fellow
University of Edinburgh, United Kingdom
Pre-reading Session Material: 1. Using routinely collected data to inform pharmaceutical policies PDF “Using Routinely Collected Data to Inform Pharmaceutical Policies” Analytical Report for OECD and EU countries https://www.oecd.org/health/health-systems/Using-Routinely-Collected-Data-to-Inform-Pharmaceutical-Policies-Analytical-Report-2019.pdf PDF “EU/EEA Country Note” https://www.oecd.org/health/health-systems/Using-Routinely-Collected-Data-to-Inform-Pharmaceutical-Policies-EU-EEA-Country-Notes-2019.pdf 2. Performance-based managed entry agreements for new medicines PDF: Performance-based managed entry agreements for new medicines in OECD countries and EU member states: How they work and possible improvements going forward https://www.oecd-ilibrary.org/docserver/6e5e4c0f-en.pdf?expires=1589794490&id=id&accname=guest&checksum=353BCB4C066F156273015FA0C91F4520
Speaker(s)
Presentation by:
Sreeram Ramagopalan, PhD, MA, MSc
F. Hoffmann-La Roche Ltd, Switzerland
Global Head Real World Data (Market Access)
Presentation by:
Karen Facey, PhD
University of Edinburgh, United Kingdom
Visiting Senior Research Fellow
Panel Discussion
Martin Wenzl, MS
Organisation For Economic Cooperation and Development, France
Health Policy Analyst, Directorate for Employment, Labour and Social Affairs
Panel Discussion
Adrian Jonas
NICE, United Kingdom
Associate Director for Data and Analytics
Panel Discussion
Christos Sotirelis
Member of the ILAP Patient and Public Reference Group, United Kingdom
Panel Discussion
Sreeram Ramagopalan, PhD, MA, MSc
F. Hoffmann-La Roche Ltd, Switzerland
Global Head Real World Data (Market Access)
Have an account?